AVTE Logo

Aerovate Therapeutics, Inc. (AVTE) 

NASDAQ
Market Cap
$73.05M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
124 of 960
Rank in Industry
87 of 550

Largest Insider Buys in Sector

AVTE Stock Price History Chart

AVTE Stock Performance

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Insider Activity of Aerovate Therapeutics, Inc.

Over the last 12 months, insiders at Aerovate Therapeutics, Inc. have bought $1.55M and sold $6.54M worth of Aerovate Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aerovate Therapeutics, Inc. have bought $71.77M and sold $8.79M worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $46.5M.

The last purchase of 928,110 shares for transaction amount of $1.55M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑06‑17.

List of Insider Buy and Sell Transactions, Aerovate Therapeutics, Inc.

2024-06-17Purchase
928,110
0.2418%
$1.67$1.55M+23.64%
2024-06-14SaleSEE REMARKS
15,000
0.0586%
$25.03$375,450-91.78%
2024-06-14SaleCHIEF TECHNICAL OFFICER
10,600
0.0413%
$25.00$265,000-91.78%
2024-06-13SaleCHIEF MEDICAL OFFICER
6,000
0.0229%
$24.50$147,000-91.70%
2024-05-17SaleCHIEF MEDICAL OFFICER
4,000
0.0136%
$21.08$84,332-89.77%
2024-05-16SaleCHIEF EXECUTIVE OFFICER
10,000
0.0347%
$21.58$215,755-90.32%
2024-05-02SaleCHIEF TECHNICAL OFFICER
1,981
0.007%
$21.02$41,631-88.79%
2024-05-01SaleCHIEF EXECUTIVE OFFICER
11,357
0.0386%
$20.34$230,946-88.77%
2024-04-17SaleCHIEF MEDICAL OFFICER
4,000
0.0143%
$22.38$89,522-88.67%
2024-04-17SaleSEE REMARKS
6,853
0.0245%
$22.37$153,327-88.67%
2024-04-16SaleCHIEF EXECUTIVE OFFICER
10,000
0.0375%
$24.70$246,971-89.29%
2024-04-10SaleSEE REMARKS
7,500
0.0268%
$26.85$201,392-90.54%
2024-04-09Saledirector
11,882
0.0428%
$28.15$334,478-90.87%
2024-04-01SaleSEE REMARKS
12,495
0.0455%
$31.23$390,208-91.67%
2024-04-01SaleSEE REMARKS
3,325
0.0124%
$31.97$106,317-91.67%
2024-04-01SaleCHIEF TECHNICAL OFFICER
5,300
0.0181%
$29.19$154,697-91.67%
2024-04-01SaleCHIEF EXECUTIVE OFFICER
10,000
0.035%
$30.00$300,033-91.67%
2024-03-28SaleCHIEF MEDICAL OFFICER
9,000
0.0322%
$29.50$265,500-91.30%
2024-03-27SaleSEE REMARKS
11,068
0.0393%
$27.97$309,519-90.87%
2024-03-25SaleSEE REMARKS
3,432
0.0129%
$28.01$96,119-90.32%

Insider Historical Profitability

<0.0001%
RA CAPITAL MANAGEMENT, L.P.
7893678
27.3379%
$2.5320<0.0001%
GRAYZEL DAVID S.director
14502
0.0502%
$2.5311<0.0001%
Sofinnova Venture Partners X, L.P.10 percent owner
3758686
13.0173%
$2.5310<0.0001%
Katabi Maha
3758686
13.0173%
$2.5310<0.0001%
Atlas Venture Fund XII, L.P.10 percent owner
3103879
10.7496%
$2.5310<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RA Capital Management, L.P.$244.37M28.698.26M0%+$00.25
Sofinnova$111.14M13.053.76M0%+$00.23
Tcg Crossover Management Llc$65.09M7.642.2M0%+$00.1
Atlas Venture Life Science Advisors Llc$60.3M7.082.04M0%+$05.6
Baker Bros Advisors LP$49.69M5.831.68M0%+$00.36
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.